Mok TS, Kim D, Wu Y, et al. Overall Survival (OS) for First-Line Crizotinib Versus Chemotherapy in ALK+ Lung Cancer: Updated Results from PROFILE 1014. ESMO 2017, abstract LBA50.
Innovatieve benaderingen voor verbeterde behandeling van NSCLC met EGFR-TKI
sep 2023 | Longoncologie